B
Belen Ferrer
Researcher at Complutense University of Madrid
Publications - 11
Citations - 1141
Belen Ferrer is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Cannabinoid & Dopamine receptor. The author has an hindex of 9, co-authored 11 publications receiving 1096 citations. Previous affiliations of Belen Ferrer include University of California, Irvine.
Papers
More filters
Journal ArticleDOI
A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding
Raquel Gómez,Miguel Navarro,Belen Ferrer,José Carlos Menéndez Gregono G. Trigo,Ainhoa Bilbao,Ignacio del Arco,Andrea Cippitelli,Felice Nava,Daniele Piomelli,Fernando Rodríguez de Fonseca +9 more
TL;DR: An unexpected role for peripheral CB1 receptors in the regulation of feeding is revealed and Capsaicin deafferentation abolished the peripheral effects of both cannabinoid agonists and antagonists, suggesting that these agents modulate food intake by acting onCB1 receptors located on capsaicin-sensitive sensory terminals.
Journal ArticleDOI
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias
TL;DR: A deficiency in endocannabinoid transmission may contribute to levodopa‐induced dyskinesias and that these complications may be alleviated by activation of CB1 receptors.
Journal ArticleDOI
Expression and function of CB1 receptor in the rat striatum: Localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors
Ana B. Martín,Emilio Fernández-Espejo,Belen Ferrer,Miguel Angel Gorriti,Ainhoa Bilbao,Miguel Navarro,Fernando Rodríguez de Fonseca,Rosario Moratalla +7 more
TL;DR: This study indicates that the endocannabinoid system is a relevant negative modulator of both dopamine D1 and D2 receptor-mediated behaviors, a finding that may contribute to the understanding of basal ganglia motor disorders.
Journal ArticleDOI
Regulation of brain anandamide by acute administration of ethanol.
Belen Ferrer,Francisco Javier Bermúdez-Silva,Ainhoa Bilbao,Lily Alvarez-Jaimes,Irene Sanchez-Vera,Andrea Giuffrida,Antonia Serrano,Elena Baixeras,Satishe Khaturia,Miguel Navarro,Loren H. Parsons,Daniele Piomelli,Fernando Rodríguez de Fonseca +12 more
TL;DR: The results suggest that receptor-mediated release of acylethanolamide is inhibited by the acute administration of ethanol, and that this effect is not derived from increased fatty acid ethanolamide degradation.
Journal ArticleDOI
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism.
Emilio Fernández-Espejo,Isabel Caraballo,Fernando Rodríguez de Fonseca,Fadwa El Banoua,Belen Ferrer,Juan A. Flores,Beatriz Galan-Rodriguez +6 more
TL;DR: The results suggest that CB1 receptor antagonists that lack psychoactive effects might be of therapeutic value in the control of very advanced stage of Parkinson's disease in humans.